Biotech Values

[DewDiligence]

EGRX—Thanks for remembering by skepticism vis-á-vis the Ryanodex NDA in ETH.

Should Eagle [have] been working on a US trial anyway?

They should have been doing that (even if only for post-marketing purposes), but today's press release strongly suggests that they haven't.

...whether or not they can get together a new full-enrolled trial by the end of summer.

That seems highly unlikely; however, the US does have many locations where hot weather lasts much of the year, so EGRX won't necessarily have to delay the trial until summer 2018.